This is a Validated Antibody Database (VAD) review about human PDCD1, based on 166 published articles (read how Labome selects the articles), using PDCD1 antibody in all methods. It is aimed to help Labome visitors find the most suited PDCD1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
PDCD1 synonym: CD279; PD-1; PD1; SLEB2; hPD-1; hPD-l; hSLE1

BioLegend
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; 1:100; loading ...
BioLegend PDCD1 antibody (Biolegend, 329920) was used in flow cytometry on human samples at 1:100. bioRxiv (2020) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2d
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 2d). Arthritis Res Ther (2020) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5b
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 5b). Sci Adv (2020) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s12a
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s12a). Nat Commun (2020) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s1
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s1). J Exp Med (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3b
BioLegend PDCD1 antibody (Biolegend, 329920) was used in flow cytometry on human samples (fig 3b). Cell Rep (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 4d
BioLegend PDCD1 antibody (Biolegend, 329918) was used in flow cytometry on human samples (fig 4d). Diagn Pathol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2b
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 2b). Front Immunol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • mass cytometry; human; loading ...; fig 2b
BioLegend PDCD1 antibody (Biolegend, 329902) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2c
BioLegend PDCD1 antibody (Biolegend, 329916) was used in flow cytometry on human samples (fig 2c). Nature (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 9a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 9a). J Exp Med (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 4a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 4a). J Virol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5d, 5e
BioLegend PDCD1 antibody (BioLegend, 329920) was used in flow cytometry on human samples (fig 5d, 5e). Cell (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...; fig 2a
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples (fig 2a). J Virol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s1d
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s1d). Proc Natl Acad Sci U S A (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1a). J Virol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; 1:100; loading ...
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples at 1:100. Nature (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...; fig 2b
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples (fig 2b). J Virol (2019) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 4c
BioLegend PDCD1 antibody (Biolegend, 329906) was used in flow cytometry on human samples (fig 4c). J Clin Invest (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3d
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3d). Clin Exp Immunol (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5h, 6k
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 5h, 6k). Cancer Res (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1b
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1b). J Clin Invest (2018) ncbi
mouse monoclonal (EH12.2H7)
  • immunohistochemistry - frozen section; human; fig 1a
  • flow cytometry; human; fig 1b
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in immunohistochemistry - frozen section on human samples (fig 1a) and in flow cytometry on human samples (fig 1b). J Exp Med (2018) ncbi
mouse monoclonal (NAT105)
  • flow cytometry; human; loading ...; fig 5a
BioLegend PDCD1 antibody (BioLegend, NKT105) was used in flow cytometry on human samples (fig 5a). Int J Infect Dis (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; hamsters; loading ...; fig s5
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on hamsters samples (fig s5). MAbs (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s2e
BioLegend PDCD1 antibody (BioLegend, 329913) was used in flow cytometry on human samples (fig s2e). Cell (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s1a
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s1a). J Immunol (2018) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s2k
In order to investigate the role of dopamine in B cell maturation in germinal centres, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s2k). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig st1
In order to investigate the effect of PD-1 expression on phagocytosis and tumour immunity, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig st1). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; tbl s3
In order to conduct a phenotypical investigation of clear cell renal cell carcinoma, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on human samples (tbl s3). Cell (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 5b
In order to find a role for IL-4 in promoting breast cancer aggressiveness, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 5b). Cancer Res (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; African green monkey; loading ...; fig s4
In order to optimize the dosing regimen of neutralizing anti-HIV-1 antibodies, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on African green monkey samples (fig s4). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s2a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s2a). Immun Ageing (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; tbl s9
In order to optimize and assess potential malaria vaccine regimens, BioLegend PDCD1 antibody (BioLegend, 329920) was used in flow cytometry on human samples (tbl s9). Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
In order to elucidate the interaction between tumor-associated and -infiltrating lymphocytes in ovarian cancer, BioLegend PDCD1 antibody (Biolegend, 329919) was used . Oncoimmunology (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; fig s4f
In order to study CXCR5+ CD8 T cells in SIV-infected animals, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples (fig s4f). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (EH12.2H7)
  • immunohistochemistry - frozen section; human; 1:100
  • flow cytometry; human
In order to characterize activated T cells in joint tissue from patients with rheumatoid arthritis, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in immunohistochemistry - frozen section on human samples at 1:100 and in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...
In order to show T cell immunoglobulin and ITIM domain expression increases over time despite early initiation of antiretroviral treatment, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Sci Rep (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; mouse; loading ...; fig 3a
In order to study the impact of modulating IFN-I signaling during suppressive combined antiretroviral therapy, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on mouse samples (fig 3a). J Clin Invest (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s2b
In order to characterize gammadelta T cell subsets from healthy humans, BioLegend PDCD1 antibody (biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s2b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s8
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig s8). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...; fig s11c
In order to assess the efficacy of targeting alpha4 beta7 integrin to treat SIV, BioLegend PDCD1 antibody (BioLegend, 329916) was used in flow cytometry on rhesus macaque samples (fig s11c). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s3a
In order to identify and characterize CXCR5hiCD44hiCD8 T cells in HIV-infected individuals, BioLegend PDCD1 antibody (Biolegend, 329908) was used in flow cytometry on human samples (fig s3a). PLoS Pathog (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1a
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1a). J Clin Invest (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig s9b
In order to explore the role of exhausted CD8 positive CXCR5 positive T cells in mice chronically infected with lymphocytic choriomeningitis virus, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig s9b). Nature (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3b
In order to utilize humanized major histocompatibility class I- and class II-deficient NOG mice to assess the antitumor effect of an anti-programmed death-1 antibody, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3b). Clin Cancer Res (2017) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...
In order to optimize vaccination with Aventis Pasteur's canarypox vector-HIV, BioLegend PDCD1 antibody (BioLegend, 329924) was used in flow cytometry on rhesus macaque samples . Nat Med (2016) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, 329904) was used . EMBO Mol Med (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig s3
BioLegend PDCD1 antibody (Biolegend, EH12-2HT) was used in flow cytometry on human samples (fig s3). Nature (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 3
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 3). Am J Transplant (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 3??
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples (fig 3??). Science (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 4, 5
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 4, 5). PLoS Pathog (2016) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 1a
In order to analyze HIV progression traits of a selective loss of early differentiated and highly functional PD1high CD4 T cells, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples (fig 1a). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...; fig 5a
In order to study the CD8+ non-cytolytic antiviral response in SIV infected rhesus macaques, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples (fig 5a). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 2a
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, BioLegend PDCD1 antibody (BioLegend, EH12.2.H7) was used in flow cytometry on human samples (fig 2a). Eur J Immunol (2016) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, 329908) was used . Nat Commun (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; fig 1
In order to assess the CD4/CD8 ratio as a marker for CD4+ T cell dysfunction in chronic HIV infection, BioLegend PDCD1 antibody (Biolegend, clone EH12.2H7) was used in flow cytometry on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (EH12.2H7)
  • blocking or activating experiments; human; fig 8
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in blocking or activating experiments on human samples (fig 8). PLoS Pathog (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Clin Immunol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to determine if HIV elite controllers have exhausted T cells, BioLegend PDCD1 antibody (Biolegend, EH12.2 H7) was used in flow cytometry on human samples . J Infect Dis (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; African green monkey; fig s4a
In order to describe the functional characteristics and dynamics of T cells in individual granulomas, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on African green monkey samples (fig s4a). PLoS Pathog (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Int J Oncol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • blocking or activating experiments; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in blocking or activating experiments on human samples . J Hepatol (2015) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples . Antimicrob Agents Chemother (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used . Clin Cancer Res (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . PLoS Pathog (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; rhesus macaque; loading ...; fig s1c
In order to explore germinal center-related hyperimmune responses and disease severity during viral infection, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on rhesus macaque samples (fig s1c). J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (EH12.2H7)
  • immunocytochemistry; human
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; 0.7:100
BioLegend PDCD1 antibody (Biolegend, EH12.2H7) was used in flow cytometry on human samples at 0.7:100. J Clin Invest (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human; loading ...; fig 1
In order to discuss the importance of assessing immune competence in cancer patients, BioLegend PDCD1 antibody (Biolegend, EH12.1) was used in flow cytometry on human samples (fig 1). Cancer Immunol Immunother (2014) ncbi
mouse monoclonal (EH12.2H7)
  • flow cytometry; human
BioLegend PDCD1 antibody (BioLegend, EH12.2H7) was used in flow cytometry on human samples . Clin Cancer Res (2012) ncbi
Invitrogen
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; 1:25; loading ...; fig 1f
Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples at 1:25 (fig 1f). elife (2020) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 5c
Invitrogen PDCD1 antibody (Thermo Fisher, PA5-20350) was used in western blot on human samples (fig 5c). Sci Adv (2020) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1a
Invitrogen PDCD1 antibody (eBioscience, 25-2799-42) was used in flow cytometry on human samples (fig 1a). J Exp Med (2019) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1c
Invitrogen PDCD1 antibody (eBioscience, eBIOJ105) was used in flow cytometry on human samples (fig 1c). Nat Med (2019) ncbi
mouse monoclonal (J116)
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...
Invitrogen PDCD1 antibody (Thermo Fisher, 14-9989-82) was used in immunohistochemistry - paraffin section on mouse samples at 1:100. Nature (2018) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 5a
Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in flow cytometry on human samples (fig 5a). J Exp Med (2018) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 7
Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in flow cytometry on human samples (fig 7). J Virol (2018) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig s10b
Invitrogen PDCD1 antibody (eBiosciences, J105) was used in flow cytometry on human samples (fig s10b). Nature (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; fig s2k
In order to investigate the role of dopamine in B cell maturation in germinal centres, Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in flow cytometry on human samples (fig s2k). Nature (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 4a
In order to demonstrate that PD-1 inhibits T cell function primarily by inactivating CD28 signaling, Invitrogen PDCD1 antibody (eBioscience, 12-9969) was used in flow cytometry on human samples (fig 4a). Science (2017) ncbi
mouse monoclonal (7A11B1)
  • immunohistochemistry - paraffin section; rat; loading ...; fig 4f
  • immunoprecipitation; rat; loading ...; fig 2b
  • immunocytochemistry; rat; loading ...; fig 5b
  • western blot; rat; loading ...; fig 3b
In order to assess the critical role of programmed death protein 1/programmed death-ligand 1 in the polarization of microglia during intracerebral hemorrhage-induced secondary brain injury, Invitrogen PDCD1 antibody (Thermo Fisher, MA5-15780) was used in immunohistochemistry - paraffin section on rat samples (fig 4f), in immunoprecipitation on rat samples (fig 2b), in immunocytochemistry on rat samples (fig 5b) and in western blot on rat samples (fig 3b). J Neuroinflammation (2017) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 6a
Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (fig 6a). Blood (2017) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1a
In order to study the restoration of immune function in chronic HIV infection, Invitrogen PDCD1 antibody (eBioscience, ebioJ105) was used in flow cytometry on human samples (fig 1a). J Clin Invest (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 6b
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, Invitrogen PDCD1 antibody (eBioscience, 17-9969-42) was used in flow cytometry on human samples (fig 6b). Oncoimmunology (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; tbl 1
In order to demonstrate that freezing already-stained samples suspended in 10% DMSO in FBS is practical and efficient way to preserve already-stained samples for mass cytometry assessment, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (tbl 1). Cytometry A (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 6a
In order to define the contribution of CD103+ tumor-infiltrating lymphocytes to high-grade serous epithelial ovarian cancer, Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in flow cytometry on human samples (fig 6a). Oncotarget (2016) ncbi
mouse monoclonal (J116)
  • blocking or activating experiments; human; 10 ug/ml; fig 5
Invitrogen PDCD1 antibody (eBioscience, 16-9989) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 5). Oncoimmunology (2016) ncbi
mouse monoclonal (J116)
  • immunohistochemistry - paraffin section; human; 1:25; loading ...; fig 1
In order to quantify the expression of programmed cell death protein 1, programmed cell death protein 1 ligand 1, and programmed cell death protein 1 ligand 2 in patients with non-small cell lung cancer, Invitrogen PDCD1 antibody (eBioscience, 14-9989-82) was used in immunohistochemistry - paraffin section on human samples at 1:25 (fig 1). Oncol Lett (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1
Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on human samples (fig 1). Stem Cells Int (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 1a
In order to generate adenoviral vaccines that express HPV-16 E6 and E7 epitopes alone or fused with p16 and assess immune responses, Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; African green monkey; fig 1
In order to study lymph node-resident simian immunodeficiency virus env-specific T follicular helper cells due to vaccine induction in Rhesus Macaques, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on African green monkey samples (fig 1). J Immunol (2016) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; 1:10
In order to utilize mass cytometry for multiplexed peptide-MHC tetramer staining, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples at 1:10. Methods Mol Biol (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; rhesus macaque; fig 2
Invitrogen PDCD1 antibody (eBioscience, 17-9969) was used in flow cytometry on rhesus macaque samples (fig 2). Nat Commun (2015) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; marmosets; loading ...; fig 4b
In order to test a therapeutic antibody against CD127 in a mouse model of experimental autoimmune encephalomyelitis, Invitrogen PDCD1 antibody (Ebiosciences, J105) was used in flow cytometry on marmosets samples (fig 4b). J Neuroimmune Pharmacol (2016) ncbi
mouse monoclonal (MIH4)
  • immunohistochemistry - frozen section; human; 1:50; fig 2
In order to investigate factors that regulate delayed-type hypersensitivity, Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in immunohistochemistry - frozen section on human samples at 1:50 (fig 2). F1000Res (2015) ncbi
mouse monoclonal (J116)
  • western blot; human; fig 2d
Invitrogen PDCD1 antibody (eBioscience, J116) was used in western blot on human samples (fig 2d). Science (2015) ncbi
mouse monoclonal (eBioJ105 (J105))
  • blocking or activating experiments; human; fig 1
Invitrogen PDCD1 antibody (eBioscience, J105) was used in blocking or activating experiments on human samples (fig 1). Nat Commun (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; mouse; 1:200; fig s9
Invitrogen PDCD1 antibody (eBioscience, 12-9969-42) was used in flow cytometry on mouse samples at 1:200 (fig s9). Nat Commun (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; fig 1
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in flow cytometry on human samples (fig 1). Cancer Immunol Res (2015) ncbi
mouse monoclonal (J116)
  • blocking or activating experiments; human; 10 ug/ml
Invitrogen PDCD1 antibody (eBioscience, J116) was used in blocking or activating experiments on human samples at 10 ug/ml. Int J Oncol (2015) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; rhesus macaque; loading ...; fig 2a
In order to assess early changes in CD4 and CD8 T cells in rhesus macaques infected with SIVMAC251, Invitrogen PDCD1 antibody (eBioscience, J105) was used in flow cytometry on rhesus macaque samples (fig 2a). J Virol (2014) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; 1.6:100
Invitrogen PDCD1 antibody (eBioscience, MIH-4) was used in flow cytometry on human samples at 1.6:100. J Clin Invest (2014) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; fig 2a
In order to test if low immune activation contributes to the viremic slow progressor phenotype, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (fig 2a). AIDS Res Hum Retroviruses (2013) ncbi
mouse monoclonal (eBioJ105 (J105))
  • flow cytometry; human; loading ...; fig 3b
In order to study the role of T regulatory cells in HIV infection, Invitrogen PDCD1 antibody (eBioscience, eBioJ105) was used in flow cytometry on human samples (fig 3b). J Virol (2011) ncbi
mouse monoclonal (MIH4)
  • immunohistochemistry - frozen section; human; fig 1
Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in immunohistochemistry - frozen section on human samples (fig 1). Arthritis Rheum (2010) ncbi
mouse monoclonal (J116)
  • flow cytometry; human; fig 1
Invitrogen PDCD1 antibody (eBioscience, J116) was used in flow cytometry on human samples (fig 1). Arthritis Rheum (2010) ncbi
mouse monoclonal (MIH4)
  • blocking or activating experiments; human; fig 6
  • flow cytometry; human; fig 4
In order to use flow cytometry to characterize cells from patients with relapsing-remitting acute or stable multiple sclerosis, Invitrogen PDCD1 antibody (eBioscience, MIH4) was used in blocking or activating experiments on human samples (fig 6) and in flow cytometry on human samples (fig 4). J Immunol (2009) ncbi
Abcam
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...
Abcam PDCD1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples . elife (2020) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4d
Abcam PDCD1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4d). Front Immunol (2019) ncbi
domestic rabbit monoclonal (EPR4877(2))
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1f
Abcam PDCD1 antibody (Abcam, EPR4877) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1f). BMC Cancer (2020) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1b
Abcam PDCD1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples (fig 1b). J Exp Med (2019) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
Abcam PDCD1 antibody (Abcam, AB52587) was used in immunohistochemistry - paraffin section on human samples (fig 2). J Clin Invest (2019) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2c
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, Abcam PDCD1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples (fig 2c). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry; human; loading ...; fig 5a
Abcam PDCD1 antibody (Abcam, NAT105) was used in immunohistochemistry on human samples (fig 5a). Oncoimmunology (2017) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4a
Abcam PDCD1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4a). J Immunol Res (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry; mouse; 1:2000; fig 5j
Abcam PDCD1 antibody (Abcam, ab52587) was used in immunohistochemistry on mouse samples at 1:2000 (fig 5j). Nat Commun (2016) ncbi
domestic rabbit monoclonal (EPR4877(2))
  • immunohistochemistry - paraffin section; human; 1:250; fig 1
Abcam PDCD1 antibody (abcam, ab137132) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 1). Nat Commun (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; fig 3
Abcam PDCD1 antibody (Abcam, NAT105) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3). Mod Pathol (2016) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2c
Abcam PDCD1 antibody (AbCam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2c). Oncoimmunology (2015) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 1b
Abcam PDCD1 antibody (Abcam, 52587) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1b). PLoS ONE (2015) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry - paraffin section; human; 1:50
Abcam PDCD1 antibody (Abcam, ab52587) was used in immunohistochemistry - paraffin section on human samples at 1:50. Blood Cancer J (2015) ncbi
mouse monoclonal (NAT105)
  • western blot; human; 1:1000; fig 4
Abcam PDCD1 antibody (Abcam, ab52587) was used in western blot on human samples at 1:1000 (fig 4). Mol Med Rep (2015) ncbi
Proteintech Group
mouse monoclonal (4H4D1)
  • western blot; human; 1:1000; loading ...; fig 6l
Proteintech Group PDCD1 antibody (Proteintech, 66220-1-lg) was used in western blot on human samples at 1:1000 (fig 6l). Aging (Albany NY) (2020) ncbi
R&D Systems
domestic goat polyclonal
  • blocking or activating experiments; human; fig 2
R&D Systems PDCD1 antibody (R&D Systems, AF1086) was used in blocking or activating experiments on human samples (fig 2). Oncotarget (2016) ncbi
domestic goat polyclonal
  • immunocytochemistry; African green monkey; fig 3
In order to study lymph node-resident simian immunodeficiency virus env-specific T follicular helper cells due to vaccine induction in Rhesus Macaques, R&D Systems PDCD1 antibody (R&D Systems, AF1086) was used in immunocytochemistry on African green monkey samples (fig 3). J Immunol (2016) ncbi
Miltenyi Biotec
mouse monoclonal (PD1.3.1.3)
  • flow cytometry; human; loading ...; fig 2b
Miltenyi Biotec PDCD1 antibody (Miltenyi Biotec, PD1.3.1.3) was used in flow cytometry on human samples (fig 2b). JCI Insight (2017) ncbi
Novus Biologicals
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
Novus Biologicals PDCD1 antibody (Novus Biologicals, NBP1-88104) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). Breast Cancer Res (2016) ncbi
Bio X Cell
mouse monoclonal (J116)
  • blocking or activating experiments; human; fig 4a
Bio X Cell PDCD1 antibody (Bio-XCell, J116) was used in blocking or activating experiments on human samples (fig 4a). Gene Ther (2015) ncbi
Cell Marque
mouse monoclonal (NAT105)
  • immunohistochemistry; human; loading ...; fig 4, 5
Cell Marque PDCD1 antibody (Cell Marque, Emergo Europe, The Hague, Netherland, NAT105) was used in immunohistochemistry on human samples (fig 4, 5). Microorganisms (2020) ncbi
mouse monoclonal (NAT105)
  • immunohistochemistry; human; loading ...
Cell Marque PDCD1 antibody (Cell Marque, NAT105) was used in immunohistochemistry on human samples . Cell (2019) ncbi
  • immunohistochemistry - paraffin section; human; 1:300; fig 1
Cell Marque PDCD1 antibody (Cell Marque, 315M-95) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 1). Oncotarget (2015) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D4W2J)
  • western blot; mouse; loading ...; fig 1c
  • western blot; human; loading ...; fig 3e
Cell Signaling Technology PDCD1 antibody (Cell signaling technology, 86163) was used in western blot on mouse samples (fig 1c) and in western blot on human samples (fig 3e). Cell Rep (2019) ncbi
domestic rabbit monoclonal (D4W2J)
  • immunohistochemistry; human; loading ...; fig 6f
Cell Signaling Technology PDCD1 antibody (Cell Signaling Technologies, 86163S) was used in immunohistochemistry on human samples (fig 6f). Cell (2019) ncbi
BD Biosciences
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2c
BD Biosciences PDCD1 antibody (BD Biosciences, 562516) was used in flow cytometry on human samples (fig 2c). elife (2020) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; 1:250; loading ...
BD Biosciences PDCD1 antibody (BD Biosciences, 562516) was used in flow cytometry on human samples at 1:250. Nature (2020) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 4a
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig 4a). J Immunol (2019) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig s7d
BD Biosciences PDCD1 antibody (BD Biosciences, 563789) was used in flow cytometry on human samples (fig s7d). Cell (2019) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig s3
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig s3). Eur J Immunol (2019) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; 1:33; loading ...; fig 6g
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples at 1:33 (fig 6g). Gastroenterology (2019) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 3a
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig 3a). Cancer (2019) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2a
BD Biosciences PDCD1 antibody (BD, EH12.1) was used in flow cytometry on human samples (fig 2a). J Virol (2018) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 2b
BD Biosciences PDCD1 antibody (BD Biosciences, MIH4) was used in flow cytometry on human samples (fig 2b). Sci Rep (2018) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2
BD Biosciences PDCD1 antibody (BD, EH12.1) was used in flow cytometry on human samples (fig 2). Biol Blood Marrow Transplant (2018) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; mouse; loading ...; tbl s1
BD Biosciences PDCD1 antibody (BD horizon, MIH4) was used in flow cytometry on mouse samples (tbl s1). Science (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 7a
BD Biosciences PDCD1 antibody (BD Biosciences, MIH4) was used in flow cytometry on human samples (fig 7a). Sci Rep (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 1
BD Biosciences PDCD1 antibody (BD Biosciences, 557946) was used in flow cytometry on human samples (fig 1). Exp Ther Med (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig 1c
In order to characterize CD8 T cells isolated patients with stage IV melanoma before and after treatment with pembrolizumab, BD Biosciences PDCD1 antibody (BD, MIH4) was used in flow cytometry on human samples (fig 1c). Nature (2017) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; mouse; loading ...
In order to assess the effects of targeting the chimeric antigen receptors to the TRAC locus, BD Biosciences PDCD1 antibody (BD biosciences, 563076) was used in flow cytometry on mouse samples . Nature (2017) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2b
BD Biosciences PDCD1 antibody (BD, EH12.1) was used in flow cytometry on human samples (fig 2b). Oncoimmunology (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig s6
BD Biosciences PDCD1 antibody (BD Biosciences, 557946) was used in flow cytometry on human samples (fig s6). Oncoimmunology (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2
BD Biosciences PDCD1 antibody (BD Pharmingen, 562516) was used in flow cytometry on human samples (fig 2). Mol Med Rep (2017) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; fig 5
In order to discuss the use of natural killer cells for clinical applications, BD Biosciences PDCD1 antibody (BD Biosciences, MIH4) was used in flow cytometry on human samples (fig 5). Cytotherapy (2017) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 5d
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, BD Biosciences PDCD1 antibody (BD, 562516) was used in flow cytometry on human samples (fig 5d). Oncoimmunology (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 2a
In order to study the contribution of T follicular helper cells to islet autoimmunity, BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 3
BD Biosciences PDCD1 antibody (BD Pharmigen, 561272) was used in flow cytometry on human samples (fig 3). Oncoimmunology (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 1
In order to test if CD4 positive T cells expressing immune checkpoint molecules are enriched in HIV-infected cells in patients receiving antiretroviral therapy, BD Biosciences PDCD1 antibody (BD, 560838) was used in flow cytometry on human samples (fig 1). PLoS Pathog (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig s1a
In order to discover that T follicular helper cells preferentially express the transcriptional coactivator Bob1, BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig s1a). Eur J Immunol (2016) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences PDCD1 antibody (BD, 557946) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...
In order to characterize B and T cells from patients with thrombocytopenia, BD Biosciences PDCD1 antibody (BD Biosciences, 558694) was used in flow cytometry on human samples . Haematologica (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 1
BD Biosciences PDCD1 antibody (BD Biosciences, EH12) was used in flow cytometry on human samples (fig 1). Oncoimmunology (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 4
BD Biosciences PDCD1 antibody (BD Bioscience, EH12.1) was used in flow cytometry on human samples (fig 4). Sci Rep (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; loading ...; fig 5a
BD Biosciences PDCD1 antibody (BD Pharmingen, EH12.1) was used in flow cytometry on human samples (fig 5a). PLoS ONE (2016) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; mouse
In order to study immune escape from CD8+ T cell killing mediated by PD-L1 expression on retrovirus-infected cells, BD Biosciences PDCD1 antibody (BD Pharmingen, MIH4) was used in flow cytometry on mouse samples . PLoS Pathog (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; fig 7
BD Biosciences PDCD1 antibody (BD Biosciences, 558694) was used in flow cytometry on human samples (fig 7). Retrovirology (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human; loading ...; fig e4a
In order to discuss the importance of IL-5 positive Th2 cells to allergies, BD Biosciences PDCD1 antibody (BD Biosciences, MIH4) was used in flow cytometry on human samples (fig e4a). J Allergy Clin Immunol (2016) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; fig 1f
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (fig 1f). PLoS Negl Trop Dis (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human
In order to study the incidence of coronary heart disease in cytomegalovirus-seropositive individuals, BD Biosciences PDCD1 antibody (BD, 558694) was used in flow cytometry on human samples . Circ Res (2015) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human; tbl 1
BD Biosciences PDCD1 antibody (BD Biosciences, EH12.1) was used in flow cytometry on human samples (tbl 1). J Gen Virol (2015) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human
BD Biosciences PDCD1 antibody (BD, MIH4) was used in flow cytometry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (EH12.1)
  • flow cytometry; human
BD Biosciences PDCD1 antibody (BD, EH12.1) was used in flow cytometry on human samples . J Exp Med (2014) ncbi
mouse monoclonal (MIH4)
  • flow cytometry; human
BD Biosciences PDCD1 antibody (BD, MIH4) was used in flow cytometry on human samples . J Exp Med (2014) ncbi
Articles Reviewed
  1. Mathew D, Giles J, Baxter A, Greenplate A, Wu J, Alanio C, et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. bioRxiv. 2020;: pubmed publisher
  2. Ryu S, Lee E, Kim D, Kim Y, Chung D, Kim J, et al. Reduction of circulating innate lymphoid cell progenitors results in impaired cytokine production by innate lymphoid cells in patients with lupus nephritis. Arthritis Res Ther. 2020;22:63 pubmed publisher
  3. Stebegg M, Bignon A, Hill D, Silva Cayetano A, Krueger C, Vanderleyden I, et al. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. elife. 2020;9: pubmed publisher
  4. Tezera L, Bielecka M, Ogongo P, Walker N, Ellis M, Garay Baquero D, et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. elife. 2020;9: pubmed publisher
  5. Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6:eaay4458 pubmed publisher
  6. Bell L, Lenhart A, Rosenwald A, Monoranu C, Berberich Siebelt F. Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. Front Immunol. 2019;10:3090 pubmed publisher
  7. Cao J, Guo Q, Guan G, Zhu C, Zou C, Zhang L, et al. Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma. Aging (Albany NY). 2020;12:1656-1684 pubmed publisher
  8. Noh B, Kwak J, Eom D. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer. 2020;20:58 pubmed publisher
  9. Sellier Y, Marliot F, Bessières B, Stirnemann J, Encha Razavi F, Guilleminot T, et al. Adaptive and Innate Immune Cells in Fetal Human Cytomegalovirus-Infected Brains. Microorganisms. 2020;8: pubmed publisher
  10. Schafflick D, Xu C, Hartlehnert M, Cole M, Schulte Mecklenbeck A, Lautwein T, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11:247 pubmed publisher
  11. Gate D, Saligrama N, Leventhal O, Yang A, Unger M, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. 2020;577:399-404 pubmed publisher
  12. Kim A, Han C, Driver I, Olow A, Sewell A, Zhang Z, et al. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells. J Immunol. 2019;203:1076-1087 pubmed publisher
  13. Canete P, Sweet R, Gonzalez Figueroa P, Papa I, Ohkura N, Bolton H, et al. Regulatory roles of IL-10-producing human follicular T cells. J Exp Med. 2019;: pubmed publisher
  14. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  15. Hill D, Pierson W, Bolland D, Mkindi C, Carr E, Wang J, et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes. J Exp Med. 2019;: pubmed publisher
  16. Han L, Hu J, Ma B, Wen D, Zhang T, Lu Z, et al. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. Diagn Pathol. 2019;14:52 pubmed publisher
  17. Lee J, Park S, Park H, Kim S, Lee J, Lee J, et al. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell. 2019;177:1842-1857.e21 pubmed publisher
  18. Thauland T, Pellerin L, Ohgami R, Bacchetta R, Butte M. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. Front Immunol. 2019;10:753 pubmed publisher
  19. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  20. Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177:556-571.e16 pubmed publisher
  21. Remmerswaal E, Hombrink P, Nota B, Pircher H, ten Berge I, van Lier R, et al. Expression of IL-7Rα and KLRG1 defines functionally distinct CD8+ T-cell populations in humans. Eur J Immunol. 2019;49:694-708 pubmed publisher
  22. Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher
  23. Lu E, Wolfreys F, Muppidi J, Xu Y, Cyster J. S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8. Nature. 2019;: pubmed publisher
  24. Karimzadeh H, Kiraithe M, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze zur Wiesch J, et al. Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. Gastroenterology. 2019;156:1820-1833 pubmed publisher
  25. Faliti C, Gualtierotti R, Rottoli E, Gerosa M, Perruzza L, Romagnani A, et al. P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. J Exp Med. 2019;216:317-336 pubmed publisher
  26. Amelio P, Portevin D, Hella J, Reither K, Kamwela L, Lweno O, et al. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. J Virol. 2019;93: pubmed publisher
  27. Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, et al. Loss of ARHGEF1 causes a human primary antibody deficiency. J Clin Invest. 2019;129:1047-1060 pubmed publisher
  28. Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25:89-94 pubmed publisher
  29. Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher
  30. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  31. Helmold Hait S, Vargas Inchaustegui D, Musich T, Mohanram V, Tuero I, Venzon D, et al. Early T Follicular Helper Cell Responses and Germinal Center Reactions Are Associated with Viremia Control in Immunized Rhesus Macaques. J Virol. 2019;93: pubmed publisher
  32. Dias J, Boulouis C, Gorin J, van den Biggelaar R, Lal K, Gibbs A, et al. The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc Natl Acad Sci U S A. 2018;115:E11513-E11522 pubmed publisher
  33. Cai Y, Abdel Mohsen M, Tomescu C, Xue F, Wu G, Howell B, et al. BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation. J Virol. 2019;93: pubmed publisher
  34. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605-609 pubmed publisher
  35. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed publisher
  36. Burton A, Pallett L, McCoy L, Suveizdyte K, Amin O, Swadling L, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603 pubmed publisher
  37. Hartana C, Ahlén Bergman E, Broome A, Berglund S, Johansson M, Alamdari F, et al. Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol. 2018;194:39-53 pubmed publisher
  38. Noto A, Procopio F, Banga R, Suffiotti M, Corpataux J, Cavassini M, et al. CD32+ and PD-1+ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. J Virol. 2018;92: pubmed publisher
  39. Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher
  40. Moysi E, Pallikkuth S, de Armas L, Gonzalez L, Ambrozak D, George V, et al. Altered immune cell follicular dynamics in HIV infection following influenza vaccination. J Clin Invest. 2018;128:3171-3185 pubmed publisher
  41. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed publisher
  42. Zhang C, Peng Y, Hublitz P, Zhang H, Dong T. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Sci Rep. 2018;8:5549 pubmed publisher
  43. Li M, Zhang W, Liu J, Li M, Zhang Y, Xiong Y, et al. Dynamic changes in the immunological characteristics of T lymphocytes in surviving patients with severe fever with thrombocytopenia syndrome (SFTS). Int J Infect Dis. 2018;70:72-80 pubmed publisher
  44. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed publisher
  45. Adler A, Bedinger D, Adams M, Asensio M, Edgar R, Leong R, et al. A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library. MAbs. 2018;10:431-443 pubmed publisher
  46. Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher
  47. Tobin L, Mavinkurve M, Carolan E, Kinlen D, O Brien E, Little M, et al. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient. JCI Insight. 2017;2: pubmed publisher
  48. Wang C, Edilova M, Wagar L, Mujib S, Singer M, Bernard N, et al. Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy. J Immunol. 2018;200:558-564 pubmed publisher
  49. Hutten T, Norde W, Woestenenk R, Wang R, Maas F, Kester M, et al. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018;24:666-677 pubmed publisher
  50. Moreno Cubero E, Subira D, Sanz de Villalobos E, Parra Cid T, Madejon A, Miquel J, et al. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol. 2018;92: pubmed publisher
  51. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  52. Sinclair C, Bommakanti G, Gardinassi L, Loebbermann J, Johnson M, Hakimpour P, et al. mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science. 2017;357:1014-1021 pubmed publisher
  53. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  54. Papa I, Saliba D, Ponzoni M, Bustamante S, Canete P, Gonzalez Figueroa P, et al. TFH-derived dopamine accelerates productive synapses in germinal centres. Nature. 2017;547:318-323 pubmed publisher
  55. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  56. Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-499 pubmed publisher
  57. Chevrier S, Levine J, Zanotelli V, Silina K, Schulz D, Bacac M, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169:736-749.e18 pubmed publisher
  58. Chen C, Sun W, Chen J, Huang J. Dynamic variations of the peripheral blood immune cell subpopulation in patients with critical H7N9 swine-origin influenza A virus infection: A retrospective small-scale study. Exp Ther Med. 2017;13:1490-1494 pubmed publisher
  59. Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher
  60. Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed publisher
  61. Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559-563 pubmed publisher
  62. Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428-1433 pubmed publisher
  63. van der Geest K, Wang Q, Eijsvogels T, Koenen H, Joosten I, Brouwer E, et al. Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study. Immun Ageing. 2017;14:5 pubmed publisher
  64. Eyquem J, Mansilla Soto J, Giavridis T, van der Stegen S, Hamieh M, Cunanan K, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-117 pubmed publisher
  65. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka A, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445-449 pubmed publisher
  66. Huang R, Francois A, McGray A, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 pubmed publisher
  67. Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2017;6:e1249558 pubmed publisher
  68. Wu J, Sun L, Li H, Shen H, Zhai W, Yu Z, et al. Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J Neuroinflammation. 2017;14:36 pubmed publisher
  69. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop H, Rooney C, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656 pubmed publisher
  70. Mylvaganam G, Rios D, Abdelaal H, Iyer S, Tharp G, Mavigner M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A. 2017;114:1976-1981 pubmed publisher
  71. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186-2197 pubmed publisher
  72. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed publisher
  73. Shan Y, Qi C, Liu Y, Gao H, Zhao D, Jiang Y. Increased frequency of peripheral blood follicular helper T cells and elevated serum IL?21 levels in patients with knee osteoarthritis. Mol Med Rep. 2017;15:1095-1102 pubmed publisher
  74. Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren H, Sonnerborg A, et al. Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017;7:40354 pubmed publisher
  75. Cheng L, Ma J, Li J, Li D, Li G, Li F, et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest. 2017;127:269-279 pubmed publisher
  76. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J Clin Invest. 2017;127:260-268 pubmed publisher
  77. Ryan P, Sumaria N, Holland C, Bradford C, Izotova N, Grandjean C, et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A. 2016;113:14378-14383 pubmed
  78. Oelsner S, Friede M, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235-249 pubmed publisher
  79. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  80. Sumatoh H, Teng K, Cheng Y, Newell E. Optimization of mass cytometry sample cryopreservation after staining. Cytometry A. 2017;91:48-61 pubmed publisher
  81. Serr I, Fürst R, Ott V, Scherm M, Nikolaev A, Gökmen F, et al. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6659-E6668 pubmed
  82. Sen D, Kaminski J, Barnitz R, Kurachi M, Gerdemann U, Yates K, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165-1169 pubmed
  83. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  84. Byrareddy S, Arthos J, Cicala C, Villinger F, Ortiz K, Little D, et al. Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science. 2016;354:197-202 pubmed
  85. Miles B, Miller S, Folkvord J, Levy D, Rakasz E, Skinner P, et al. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection. PLoS Pathog. 2016;12:e1005924 pubmed publisher
  86. Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130-75144 pubmed publisher
  87. Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher
  88. Daud A, Loo K, Pauli M, Sanchez Rodriguez R, Sandoval P, Taravati K, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447-52 pubmed publisher
  89. He R, Hou S, Liu C, Zhang A, Bai Q, Han M, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 2016;537:412-428 pubmed publisher
  90. Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
  91. Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, et al. Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology. 2016;5:e1114203 pubmed publisher
  92. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  93. Chen Z, Mei J, Liu L, Wang G, Li Z, Hou J, et al. PD-L1 expression is associated with advanced non-small cell lung cancer. Oncol Lett. 2016;12:921-927 pubmed
  94. Fromentin R, Bakeman W, Lawani M, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12:e1005761 pubmed publisher
  95. Vaccari M, Gordon S, Fourati S, Schifanella L, Liyanage N, Cameron M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22:762-70 pubmed publisher
  96. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-11 pubmed publisher
  97. Ruibal P, Oestereich L, Lüdtke A, Becker Ziaja B, Wozniak D, Kerber R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100-4 pubmed publisher
  98. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18:43 pubmed publisher
  99. Yamashita K, Kawata K, Matsumiya H, Kamekura R, Jitsukawa S, Nagaya T, et al. Bob1 limits cellular frequency of T-follicular helper cells. Eur J Immunol. 2016;46:1361-70 pubmed publisher
  100. Saito H, Okita K, Fusaki N, Sabel M, Chang A, Ito F. Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells. Stem Cells Int. 2016;2016:8394960 pubmed publisher
  101. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  102. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  103. Flint S, Gibson A, Lucas G, Nandigam R, Taylor L, Provan D, et al. A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia. Haematologica. 2016;101:698-706 pubmed publisher
  104. Friedman K, Brodsky A, Lu S, Wood S, Gill A, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29:528-41 pubmed publisher
  105. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, et al. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology. 2016;5:e1104448 pubmed
  106. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  107. Black M, Barsoum I, Truesdell P, Cotechini T, Macdonald Goodfellow S, PETROFF M, et al. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. 2016;7:10557-67 pubmed publisher
  108. Garcia Bates T, Kim E, Concha Benavente F, Trivedi S, Mailliard R, Gambotto A, et al. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. J Immunol. 2016;196:2870-8 pubmed publisher
  109. Su S, Hu B, Shao J, Shen B, Du J, Du Y, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070 pubmed publisher
  110. Li L, Jiang Y, Lao S, Yang B, Yu S, Zhang Y, et al. Mycobacterium tuberculosis-Specific IL-21+IFN-γ+CD4+ T Cells Are Regulated by IL-12. PLoS ONE. 2016;11:e0147356 pubmed publisher
  111. Vargas Inchaustegui D, Demers A, Shaw J, Kang G, Ball D, Tuero I, et al. Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques. J Immunol. 2016;196:1700-10 pubmed publisher
  112. Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, et al. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog. 2016;12:e1005372 pubmed publisher
  113. Paris R, Petrovas C, Ferrando Martinez S, Moysi E, Boswell K, Archer E, et al. Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE. 2015;10:e0144767 pubmed publisher
  114. Javed A, Leuchte N, Neumann B, Sopper S, Sauermann U. Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques. PLoS ONE. 2015;10:e0142086 pubmed publisher
  115. Leong M, Newell E. Multiplexed Peptide-MHC Tetramer Staining with Mass Cytometry. Methods Mol Biol. 2015;1346:115-31 pubmed publisher
  116. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  117. Akhmetzyanova I, Drabczyk M, Neff C, Gibbert K, Dietze K, Werner T, et al. PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog. 2015;11:e1005224 pubmed publisher
  118. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  119. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed publisher
  120. Mitson Salazar A, Yin Y, Wansley D, Young M, Bolan H, Arceo S, et al. Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subpopulation with enhanced function. J Allergy Clin Immunol. 2016;137:907-18.e9 pubmed publisher
  121. Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology. 2015;4:e1026530 pubmed
  122. Frederiksen J, Buggert M, Noyan K, Nowak P, Sönnerborg A, Lund O, et al. Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. PLoS ONE. 2015;10:e0137635 pubmed publisher
  123. Schmidt L, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch J, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE. 2015;10:e0136023 pubmed publisher
  124. Chen X, Li W, Zhang Y, Song X, Xu L, Xu Z, et al. Distribution of Peripheral Memory T Follicular Helper Cells in Patients with Schistosomiasis Japonica. PLoS Negl Trop Dis. 2015;9:e0004015 pubmed publisher
  125. Dunham J, Lee L, van Driel N, Laman J, Ni I, Zhai W, et al. Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis. J Neuroimmune Pharmacol. 2016;11:73-83 pubmed publisher
  126. Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
  127. Yoon K, Byun S, Kwon E, Hwang S, Chu K, Hiraki M, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349:1261669 pubmed publisher
  128. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  129. Lee J, Jeong I, Joh J, Jung Y, Sim S, Choi B, et al. Differential expression of CD57 in antigen-reactive CD4+ T cells between active and latent tuberculosis infection. Clin Immunol. 2015;159:37-46 pubmed publisher
  130. Pombo C, Wherry E, Gostick E, Price D, Betts M. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers. J Infect Dis. 2015;212:1376-86 pubmed publisher
  131. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell L, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692 pubmed publisher
  132. Pratama A, Srivastava M, Williams N, Papa I, Lee S, Dinh X, et al. MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. Nat Commun. 2015;6:6436 pubmed publisher
  133. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  134. Yang Z, Grote D, Ziesmer S, Xiu B, Novak A, Ansell S. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015;5:e281 pubmed publisher
  135. Gideon H, Phuah J, Myers A, Bryson B, Rodgers M, Coleman M, et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11:e1004603 pubmed publisher
  136. Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed
  137. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  138. Tsukahara T, Iwase N, Kawakami K, Iwasaki M, Yamamoto C, Ohmine K, et al. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene Ther. 2015;22:209-15 pubmed publisher
  139. Hoffmann J, Shmeleva E, Boag S, Fiser K, Bagnall A, Murali S, et al. Myocardial ischemia and reperfusion leads to transient CD8 immune deficiency and accelerated immunosenescence in CMV-seropositive patients. Circ Res. 2015;116:87-98 pubmed publisher
  140. Gao F, Wang W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep. 2015;11:1200-6 pubmed publisher
  141. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2015;46:28-36 pubmed publisher
  142. Fujita T, Burwitz B, Chew G, Reed J, Pathak R, Seger E, et al. Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol. 2014;193:5576-83 pubmed publisher
  143. Gerna G, Lilleri D, Fornara C, Bruno F, Gabanti E, Cane I, et al. Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. J Gen Virol. 2015;96:360-9 pubmed publisher
  144. Kudernatsch R, Letsch A, Guerreiro M, Löbel M, Bauer S, Volk H, et al. Human bone marrow contains a subset of quiescent early memory CD8(+) T cells characterized by high CD127 expression and efflux capacity. Eur J Immunol. 2014;44:3532-42 pubmed publisher
  145. Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J Exp Med. 2014;211:2033-45 pubmed publisher
  146. Kurktschiev P, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Wendtner C, et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med. 2014;211:2047-59 pubmed publisher
  147. Langhans B, Alwan A, Krämer B, Glässner A, Lutz P, Strassburg C, et al. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol. 2015;62:398-404 pubmed publisher
  148. Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother. 2014;58:6790-806 pubmed publisher
  149. Herati R, Reuter M, Dolfi D, Mansfield K, Aung H, Badwan O, et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol. 2014;193:3528-37 pubmed publisher
  150. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res. 2014;20:5052-63 pubmed publisher
  151. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  152. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson M, Michaelsson J, et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 2014;10:e1004251 pubmed publisher
  153. Kenway Lynch C, Das A, Lackner A, Pahar B. Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection. J Virol. 2014;88:9442-57 pubmed publisher
  154. Hong J, Amancha P, Rogers K, Courtney C, Havenar Daughton C, Crotty S, et al. Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol. 2014;193:797-806 pubmed publisher
  155. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  156. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  157. Buggert M, Norstr m M, Salemi M, Hecht F, Karlsson A. Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression. J Immunol. 2014;192:4685-96 pubmed publisher
  158. Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246-59 pubmed publisher
  159. Lanteri M, Diamond M, Law J, Chew G, Wu S, Inglis H, et al. Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection. PLoS ONE. 2014;9:e92134 pubmed publisher
  160. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  161. Chang S, Kohrt H, Maecker H. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63:713-9 pubmed publisher
  162. Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-70 pubmed publisher
  163. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed publisher
  164. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34 pubmed publisher
  165. Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher
  166. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher